2020
Immuron (ASX:IMC) reveals positive anti-diarrhoea vaccine results
9 November 2020
Immuron (IMC) is surging on the ASX today after revealing some encouraging progress in the development of a treatment for diarrhoea.
Immuron (ASX:IMC) takes steps towards FDA approval for stomach bug treatment
12 October 2020
Biopharma company Immuron (IMC) is set to start clinical trials of its candidate drug, IMM124E, in collaboration with the U.S.-based Uniformed Services University.
Immuron’s commercially available products found to neutralise COVID-19 during in vitro research
21 July 2020
Biopharmaceutical company Immuron (ASX: IMC) has revealed the IMM-124E, which is used in its commercially available Travelan product, has demonstrated neutralising activity against COVID-19.
Immuron (ASX:IMC) develops research agreement
22 June 2020
Biopharmaceutical company Immuron (IMC) has executed its previously announced research agreement involving the US Naval Medical Research Centre and the CSIRO.
Immuron and US Naval Medical Research Center prepare to develop novel oral therapeutic for E-Coli
10 June 2020
Dual-listed biopharmaceutical company Immuron (ASX: IMC) is on course to make progress with a new oral therapeutic to treat campylobacteriosis and E. coli infections after development partner Naval Medical Research Center (NMRC) requested a pre-IND....
